ABSTRACT
ABSTRACT: Increasing evidence suggests that early-life bacillus Calmette-Guérin (BCG) vaccine could prevent atopic eczema through its beneficial off-target effects. In this meta-analysis, 3 randomized control trials with similar methods were included and enabled robust estimations with low heterogeneity, involving a total of 5655 children randomized to early-life BCG Denmark (n = 2832) or no BCG (n = 2823). Meta-analyses suggest a beneficial effect of BCG to prevent eczema (risk ratio [RR], 0.89; 95% confidence interval [CI], 0.82-0.98). In subgroup analyses, BCG was more beneficial in boys (RR, 0.84; 95% CI, 0.74-0.95) and in children born to 2 atopic parents (RR, 0.81; 95% CI, 0.68-0.97). The NNT to prevent one case of eczema among children of 1 or 2 atopic parent was 20 (95% CI, 12-50). Bacillus Calmette-Guérin Denmark leads to an 11% reduction in the risk of eczema in early life. A greater effect was observed with increasing predisposition. Given its well-established safety profile, neonatal BCG vaccination should be considered for children of atopic parents.
Subject(s)
Dermatitis, Atopic , Eczema , Humans , Infant, Newborn , Male , Child , BCG Vaccine , Vaccination , Eczema/prevention & control , Odds Ratio , Dermatitis, Atopic/prevention & control , Randomized Controlled Trials as TopicABSTRACT
BACKGROUND: Sensitization means elevated number of specific immunoglobulin E, either measured by skin prick test or in blood samples. Sensitization is associated with, but not synonymous with, allergic disease. METHODS: The Danish Calmette Study was conducted from 2012 to 2015 at three Danish hospitals, with the aim of exploring nonspecific effects of neonatal Bacillus Calmette-Guérin vaccination. Participants at Kolding Hospital were invited to have a blood sample analyzed for allergic sensitization at 13 months of age. Telephone interviews gave information about allergic symptoms, and the children were examined for signs of atopic dermatitis at 3 and 13 months. RESULTS: Of the 1241 children included in the Danish Calmette Study in Kolding 1066 (86%) had a blood sample drawn, representing 36% of the invited families. The blood sample cohort had a relatively high percentage of atopic predisposition (66.6%) and most mothers had a medium or long education. We found 90 infants (8.4%) to be sensitized, with sensitization against food items (milk, egg, peanut, and hazelnut) being the most common. Atopic dermatitis was found in 19% of the children, and it was significantly associated with sensitization against egg, peanut, wheat, cat, and dog. CONCLUSION: In a partly selected Danish cohort, sensitization was present in 8% at 13 months of age, especially sensitization against food items. Children with atopic dermatitis were significantly more sensitized (16.6%). However, most sensitized children did not have any allergic symptoms at this age.
Subject(s)
Allergens/blood , Dermatitis, Atopic/blood , Food Hypersensitivity/blood , Hypersensitivity/blood , Immunoglobulin E/blood , Allergens/immunology , Animals , Cats , Cohort Studies , Denmark , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/immunology , Dogs , Female , Food Hypersensitivity/diagnosis , Food Hypersensitivity/immunology , Humans , Hypersensitivity/diagnosis , Hypersensitivity/immunology , Immunoglobulin E/immunology , Infant , MaleABSTRACT
BACKGROUND: Childhood infections are common and Bacillus Calmette-Guérin (BCG) vaccination at birth may prevent these via nonspecific effects. METHODS: A randomized, clinical multicenter trial. All women planning to give birth (n = 16,521) at the three study sites were invited during the recruitment period. Participating children were randomized to receive BCG within 7 d of birth or to a no intervention control group. Parent-reported infections (events) were collected using telephone interviews at 3 and 13 mo. Data collectors were blinded to allocation. RESULTS: The analyses included 4,224/4,262 (99%) and 4,192/4,262 (98%) children at 3 and 13 mo. From 0 to 3 mo, there were 291 events in the BCG group vs. 336 events in the control group, incidence rate ratio (IRR) = 0.87 (95% confidence interval (CI): 0.72 to 1.05). In this age group, the IRR was 0.62 (95% CI: 0.39 to 0.98) if the mother was BCG vaccinated. From 3 to 13 mo, there were 7,028 vs. 6,791 events, IRR = 1.02 (95% CI: 0.97 to 1.07). CONCLUSION: This study did not find a nonspecific public health benefit of BCG on parent-reported infections. BCG may have reduced the incidence of infections in children of BCG-vaccinated mothers during the first 3 mo.
